Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sophie Vieujean, Edouard Louis, Silvio Danese & Laurent Peyrin-Biroulet. (2023) A critical review of ustekinumab for the treatment of active ulcerative colitis in adults. Expert Review of Gastroenterology & Hepatology 17:5, pages 413-430.
Read now
Read now
Ferdinando D’Amico, Gionata Fiorino, Federica Furfaro, Mariangela Allocca, Giulia Roda, Laura Loy, Alessandra Zilli, Virginia Solitano, Laurent Peyrin-Biroulet & Silvio Danese. (2020) Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Review of Gastroenterology & Hepatology 14:9, pages 765-773.
Read now
Read now
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone & Ambrogio Orlando. (2020) Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies. Expert Opinion on Biological Therapy 20:2, pages 193-203.
Read now
Read now
Anja Eberl, Taru Hallinen, Clas-Göran af Björkesten, Markku Heikkinen, Eija Hirsi, Mikko Kellokumpu, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Heikki Nuutinen, Ulla-Maija Suhonen, Karri Utriainen, Ilkka Vihriälä, Erkki Soini, Christina Wennerström, Riikka Nissinen, Andras Borsi, Minni Koivunen, Jyrki Tillonen & Taina Sipponen. (2019) Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scandinavian Journal of Gastroenterology 54:6, pages 718-725.
Read now
Read now
Fabio Salvatore Macaluso, Ambrogio Orlando & Mario Cottone. (2019) Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opinion on Biological Therapy 19:2, pages 89-98.
Read now
Read now
Zachary A. Borman, Justin Côté-Daigneault & Jean-Frédéric Colombel. (2018) The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Review of Gastroenterology & Hepatology 12:11, pages 1101-1108.
Read now
Read now
Paulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi & Remo Panaccione. (2018) Clinical utility of ustekinumab in Crohn’s disease. Journal of Inflammation Research 11, pages 35-47.
Read now
Read now
Articles from other publishers (35)
Nisha B. Shah, Autumn D. Zuckerman, Katie R. Hosteng, Jessica Fann, Josh DeClercq, Leena Choi, Laura Cherry, David A. Schwartz & Sara Horst. (2023) Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences 68:12, pages 4331-4338.
Crossref
Crossref
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Wolfgang Mohl, Niels Teich, Martin Hoffstadt, Axel Schweitzer, Manfred von der Ohe, Annika Gauss, Raja Atreya, Thomas Krause, Irina Blumenstein, Petra Hartmann & Stefan Schreiber. (2023) Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn’s Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study. Inflammatory Bowel Diseases 29:11, pages 1741-1750.
Crossref
Crossref
Hiroaki Okuda, Shuhei Hosomi, Shigehiro Itani, Noriyuki Kurimoto, Yumie Kobayashi, Rieko Nakata, Yu Nishida, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Noriko Kamata, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Satoko Ohfuji & Yasuhiro Fujiwara. (2023) Pretreatment serum monocyte chemoattractant protein‐1 as a predictor of long‐term outcome by ustekinumab in patients with Crohn's disease. Journal of Gastroenterology and Hepatology 38:6, pages 910-920.
Crossref
Crossref
T Yoshihara, S Shinzaki, H Iijima, Y Tsujii, Y Hayashi & T Takehara. (2023) Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta‐analyses. Journal of Gastroenterology and Hepatology 38:5, pages 830-832.
Crossref
Crossref
Remo Panaccione, Wan-Ju Lee, Ryan Clark, Kristina Kligys, Rhiannon I. Campden, Stacy Grieve & Tim Raine. (2023) Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review. Advances in Therapy 40:5, pages 2051-2081.
Crossref
Crossref
He Zhou, Fang Wang, Jian Wan, Song Su, Yanting Shi, Xiaofei Li, Tong Wu & Jie Liang. (2023) Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries. Journal of Clinical Medicine 12:5, pages 1894.
Crossref
Crossref
Amanda M. JohnsonMaria BarskyWaseem AhmedSamantha ZullowJonathan GalatiVipul JairathNeeraj NarulaFarhad PeeraniBenjamin H. ClickElliot S. CoburnThucNhi Tran DangStephanie GoldManasi AgrawalRajat GargManik AggarwalDanah MohammadBrendan HalloranGursimran S. KochharHannah TodorowskiNabeeha Mohy Ud DinJames IzanecAmanda TeepleChris GasinkErik MuserZhijie DingArun SwaminathKomal LakhaniDan HoganSamit DattaRyan C. UngaroBrigid S. BolandMatthew BohmMonika FischerSashidhar SagiAnita AfzaliThomas UllmanGarrett LawlorDaniel C. BaumgartShannon ChangDavid HudesmanDana LukinEllen J. ScherlJean-Frederic ColombelBruce E. SandsCorey A. SiegelMiguel RegueiroWilliam J. SandbornDavid BruiningSunanda KaneEdward V. LoftusParambir S. Dulai. (2023) The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. American Journal of Gastroenterology 118:2, pages 317-328.
Crossref
Crossref
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi & Byong Duk Ye. (2023) Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intestinal Research 21:1, pages 137-147.
Crossref
Crossref
Sophie Vieujean & Edouard Louis. (2023) Precision medicine and drug optimization in adult inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology 16, pages 175628482311733.
Crossref
Crossref
Anders Forss, Mark Clements, Pär Myrelid, Hans Strid, Charlotte Söderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olén, Jonas Halfvarson & Jonas F. Ludvigsson. (2022) Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease. Digestive Diseases and Sciences 68:1, pages 65-76.
Crossref
Crossref
María Chaparro, Iria Baston-Rey, Estela Fernández-Salgado, Javier González García, Laura Ramos, María Teresa Diz-Lois Palomares, Federico Argüelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Núñez Ortiz, Mara Charro, Daniel Ginard, Carmen Dueñas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutiérrez Casbas, Patricia Ramírez de la Piscina, Marta Maia Boscá-Watts, Maite Arroyo, María José García, Esther Hinojosa, Jordi Gordillo, Pilar Martínez Montiel, Benito Velayos Jiménez, Cristina Quílez Ivorra, Juan María Vázquez Morón, José María Huguet, Yago González-Lama, Ana Isabel Muñagorri Santos, Víctor Manuel Amo, María Dolores Martín-Arranz, Fernando Bermejo, Jesús Martínez Cadilla, Cristina Rubín de Célix, Paola Fradejas Salazar, Antonio López San Román, Nuria Jiménez, Santiago García López, Anna Figuerola, Itxaso Jiménez, Francisco José Martínez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernández Camba, Francisco Javier García-Alonso, Manuel Van Domselaar, Ramón Pajares Villarroya, Alejandro Núñez, Francisco Rodríguez Moranta, Ignacio Marín-Jiménez, Virginia Robles Alonso, María del Mar Martín Rodríguez, Patricia Camo-Monterde, Iván García Tercero, Mercedes Navarro Llavat, Lara Arias García, Daniel Hervías Cruz, Sara Sulleiro, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta & Javier P Gisbert. (2022) Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study. Inflammatory Bowel Diseases 28:11, pages 1725-1736.
Crossref
Crossref
Cristina Rubín de Célix, María Chaparro & Javier P. Gisbert. (2022) Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies. Journal of Clinical Medicine 11:14, pages 4202.
Crossref
Crossref
Mohammed Assem Khorshid, Ahmed Cordie & Sherief Abd-Elsalam. (2022) Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis. Journal of Coloproctology 42:02, pages 178-186.
Crossref
Crossref
Sailish Honap, Susanna Meade, Hajir Ibraheim, Peter M. Irving, Michael P. Jones & Mark A. Samaan. (2021) Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences 67:3, pages 1018-1035.
Crossref
Crossref
Andrea Cassinotti, Alberto Batticciotto, Marco Parravicini, Maurizio Lombardo, Paolo Radice, Claudio Camillo Cortelezzi, Simone Segato, Federico Zanzi, Antonella Cappelli & Sergio Segato. (2022) Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therapeutic Advances in Gastroenterology 15, pages 175628482210858.
Crossref
Crossref
Javier P. Gisbert & María Chaparro. (2021) Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. Journal of Clinical Medicine 10:22, pages 5318.
Crossref
Crossref
Tessa Straatmijer, Vince B C Biemans, Frank Hoentjen, Nanne K H de Boer, Alexander G L Bodelier, Gerard Dijkstra, Willemijn A van Dop, Jeoffrey J L Haans, Jeroen M Jansen, P W Jeroen Maljaars, Sander van der Marel, Bas Oldenburg, Cyriel Y Ponsioen, Marijn C Visschedijk, Annemarie C de Vries, Rachel L West, C Janneke van der Woude, Marieke Pierik, Marjolijn Duijvestein & Andrea E van der Meulen-de Jong. (2021) Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis 15:11, pages 1920-1930.
Crossref
Crossref
Seiji Yokoyama, Teita Asano, Katsumasa Nagano, Hiroaki Tsuchiya, Masayuki Takagishi, Shigeharu Tsujioka, Naomi Miura & Takayuki Matsumoto. (2021) Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan. Journal of Gastroenterology and Hepatology 36:11, pages 3069-3076.
Crossref
Crossref
Kei Nishioka, Haruei Ogino, Takatoshi Chinen, Eikichi Ihara, Yoshimasa Tanaka, Kazuhiko Nakamura & Yoshihiro Ogawa. (2021) Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease. Journal of Gastroenterology 56:11, pages 976-987.
Crossref
Crossref
Takeo Yoshihara, Shinichiro Shinzaki, Takahiro Amano, Hideki Iijima, Tetsuo Takehara, Nagamu Inoue, Motoi Uchino, Motohiro Esaki, Taku Kobayashi, Masayuki Saruta, Ken Sugimoto, Shiro Nakamura, Keisuke Hata, Fumihito Hirai, Sakiko Hiraoka, Toshimitsu Fujii, Minoru Matsuura, Katsuyoshi Matsuoka, Kenji Watanabe, Hiroshi Nakase & Mamoru Watanabe. (2021) Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 36:7, pages 1744-1753.
Crossref
Crossref
Jana G. Hashash & Fadi H. Mourad. (2021) Positioning biologics in the management of moderate to severe Crohn's disease. Current Opinion in Gastroenterology 37:4, pages 351-356.
Crossref
Crossref
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu Inoue, Toshiyuki Itoh, Makoto Naganuma, Tadakazu Hisamatsu, Mamoru Watanabe, Hiroto Miwa, Nobuyuki Enomoto, Tooru Shimosegawa & Kazuhiko Koike. (2021) Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. Journal of Gastroenterology 56:6, pages 489-526.
Crossref
Crossref
Ana Gutiérrez & Iago Rodríguez-Lago. (2021) How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Frontiers in Medicine 8.
Crossref
Crossref
L. Monin, S. Dubois, C. Reenaers, C. Van Kemseke, P. Latour, D. Van Daele, S Vieujean, L. Seidel & E. Louis. (2021) Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort.. Digestive and Liver Disease 53:1, pages 72-78.
Crossref
Crossref
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur & H. J. M. J. Crijns. (2020) Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review. Drugs 80:16, pages 1699-1722.
Crossref
Crossref
Javier P Gisbert & María Chaparro. (2020) Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 14:5, pages 694-709.
Crossref
Crossref
Ariella Bar‐Gil Shitrit, Ami Ben‐Ya’acov, Matan Siterman, Matti Waterman, Ayal Hirsh, Doron Schwartz, Eran Zittan, Yehonatan Adler, Benjamin Koslowsky, Irit Avni‐Biron, Yehuda Chowers, Yulia Ron, Eran Israeli, Bella Ungar, Henit Yanai, Nitsan Maharshak, Shomron Ben‐Horin, Rami Eliakim, Iris Dotan, Eran Goldin & Uri Kopylov. (2020) Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study. United European Gastroenterology Journal 8:4, pages 418-424.
Crossref
Crossref
Laura Lorenzo González, Teresa Valdés Delgado, Juan María Vázquez Morón, Luisa Castro Laria, Eduardo Leo Carnerero, María Belén Maldonado Pérez, Damián Sánchez Capilla, Héctor Pallarés Manrique, Antonia Sáez Díaz & Federico Argüelles Arias. (2020) Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Syedreza A. Haider, Abhijeet Yadav, Courtney Perry, Leon Su, Olalekan Akanbi, Praneeth Kudaravalli, Nishant Tripathi, Mahmoud A. Hashim, Mohammed Abdelsalam, Mohamed Hussein, Ahmed Elkheshen, Vihang Patel, Saad Emhmed Ali, Latoya Lamb, Karen Ingram, Casie Mayne, Amy B. Stuffelbeam, Deborah Flomenhoft, Arnold Stromberg & Terrence A. Barrett. (2020) Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease. Therapeutic Advances in Gastroenterology 13, pages 175628482095924.
Crossref
Crossref
Vince B C Biemans, Andrea E van der Meulen - de Jong, Christine J van der Woude, Mark Löwenberg, Gerard Dijkstra, Bas Oldenburg, Nanne K H de Boer, Sander van der Marel, Alexander G L Bodelier, Jeroen M Jansen, Jeoffrey J L Haans, Rosaline Theeuwen, Dirk de Jong, Marie J Pierik & Frank Hoentjen. (2020) Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis 14:1, pages 33-45.
Crossref
Crossref
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Crossref
Tal Engel, Diana E. Yung, Christopher Ma, Benjamin Pariente, Pauline WIls, Rami Eliakim, Bella Ungar, Shomron Ben-Horin & Uri Kopylov. (2019) Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Digestive and Liver Disease 51:9, pages 1232-1240.
Crossref
Crossref
M. Iborra, B. Beltrán, A. Fernández‐Clotet, A. Gutiérrez, B. Antolín, J.M. Huguet, R. De Francisco, O. Merino, D. Carpio, S. García‐López, F. Mesonero, P. Navarro, R. Ferreiro‐Iglesias, A.Y. Carbajo, M. Rivero, J.P. Gisbert, M.C. Piñero‐Pérez, D. Monfort, L. Bujanda, M.F. García‐Sepulcre, A. Martín‐Cardona, F. Cañete, C. Taxonera, E. Domènech & P. Nos. (2019) Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry. Alimentary Pharmacology & Therapeutics 50:3, pages 278-288.
Crossref
Crossref
Elham Rahme, Hacene Nedjar & Waqqas Afif. (2019) Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization. Journal of the Canadian Association of Gastroenterology.
Crossref
Crossref
Marjorie C. Argollo, Mariangela Allocca, Federica Furfaro, Laurent Peyrin-Biroulet & Silvio Danese. (2019) Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. Current Pharmaceutical Design 25:1, pages 25-31.
Crossref
Crossref